Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Post-Immunotherapy in RCC (AT ASIA)
NCT04714697Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04714697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714697.